Novo Nordisk CEO Mike Doustdar, brought in last year to revitalize the Danish drugmaker after it lost GLP-1 marketing ground to Eli Lilly, is taking a measured line on the company's corporate rebrand. He says he does not make changes for the sake of change, according to reports from Fierce Pharma and Fierce Biotech.
The two outlets published identical coverage, so their accounts fully agree. Doustdar frames the rebrand as an effort to honor Novo's heritage while planning for the future, and he describes himself as 'still a bull' on the company's prospects.
The comments suggest a leadership style rooted in continuity rather than disruption, even as Novo works to regain its competitive footing. Neither report offers specifics on pipeline plans or the timeline for the rebrand.